Compare IDEXX Laboratories, Inc. (IDXX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Vanguard High Dividend Yield ETF trades at $158.9 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 2.5× IDEXX Laboratories, Inc.'s market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vanguard High Dividend Yield ETF for 139 Days on average.
| IDXX | VYM | |
|---|---|---|
Market Cap | $40.43B | $100.80B |
Volume | 692,164 | 908,176 |
Sector | Health | — |
52-Week High | $766.68 | $167.03 |
52-Week Low | $504.70 | $137.47 |
Typical Hold Time | 46 Days | 139 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
VYM trades at $158.75, up 0.83% with a bearish technical signal from moving averages. The ETF maintains consistent dividend payments, with a recent $0.89 dividend declared for September 2026. Technical indicators show mixed signals with neutral oscillators and key support at $156. Recent media coverage highlights VYM's role in income strategies but notes competitive pressure from alternative dividend ETFs offering higher yields and performance.
VYM faces headwinds from underperformance relative to peers like SCHD and IDV, with concerns about dividend sustainability in its holdings. The ETF's broad diversification provides stability but limits upside potential. Key risks include sector concentration in dividend-cut vulnerable stocks and competitive yield pressures. Analyst sentiment remains neutral given its steady but modest income profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
